Drug intelligence / Profile preview

XL080

Development stage: Preclinical
Lead developer: XL-protein
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

XL080 is a preclinical-stage PASylated protein therapeutic being developed by XL-protein for the treatment of infectious and inflammatory diseases. The drug consists of interferon-alpha (IFN-alpha) genetically fused to a conformationally disordered polypeptide sequence composed of proline, alanine, and serine (PAS). This proprietary PASylation technology increases the hydrodynamic volume of the cytokine, thereby reducing renal filtration and significantly extending its plasma half-life. By improving the pharmacokinetic profile of IFN-alpha, XL080 aims to provide a more convenient dosing regimen and potentially improved tolerability compared to non-modified or PEGylated interferon therapies.

Other names: PAS-IFN-alphaPASylated interferon-alpha

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on XL080.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XL080.

Explore the full profile